RxDoctor Payments Data

Jasmine Lester

Family · Hernando, MSNPI 1851902860

Payments from drug & device makers

$3,660in general payments, 2019–2025

Across 191 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$927
  • Boehringer Ingelheim$359
  • AstraZeneca$291
  • Actelion Pharmaceuticals US, Inc.$196
  • Sanofi$196
  • Mylan Specialty L.p.$188
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$3,660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,660 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$66,064
Medicare patients
420
Services billed
1,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat12$169,052
Trelegy ElliptaFluticasone/Umeclidin/Vilanter86$63,902
Dupixent PenDupilumab13$48,453
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$28,119
SymbicortBudesonide/Formoterol Fumarate13$3,806
Albuterol Sulfate HfaAlbuterol Sulfate136$3,713
Roflumilast14$2,224
Ventolin HfaAlbuterol Sulfate15$933
Azelastine Hcl24$622
Fluticasone Propionate29$350
Azithromycin22$323
Levocetirizine Dihydrochloride39$286
Prednisone56$232
Montelukast Sodium29$133
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$83$169,05212 claims
GSKTrelegy Ellipta$927$63,90286 claims
AstraZenecaBreztri Aerosphere, Symbicort$291$31,92551 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.

Other family in Hernando

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →